HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

tetulomab tetraxetan lu-177

used to treat non-Hodgkin's lymphoma

Also Known As:

177LU-DOTA-HH1; 177LU-tetraxetan-tetulomab; 177Lu-tetulomab; betalutin

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        tetulomab tetraxetan lu-177: 3
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        tetulomab tetraxetan lu-177: 3
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        tetulomab tetraxetan lu-177: 3

Experts

1.	Dahle, Jostein: 3 articles (01/2019 - 01/2014)
2.	Patzke, Sebastian: 2 articles (01/2019 - 01/2015)
3.	Larsen, Roy H: 2 articles (01/2015 - 01/2014)
4.	Repetto-Llamazares, Ada H V: 2 articles (01/2015 - 01/2014)
5.	Bertoni, Francesco: 1 article (01/2019)
6.	Generalov, Roman: 1 article (01/2019)
7.	Gilani, Sania: 1 article (01/2019)
8.	Melhus, Katrine: 1 article (01/2019)
9.	Rødland, Gro Elise: 1 article (01/2019)
10.	Syljuåsen, Randi G: 1 article (01/2019)

Related Diseases

1.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/01/2019 - "The CD37 targeting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin) is currently being evaluated in a clinical phase 2b trial for patients with follicular lymphoma (FL) and in a phase 1 trial for patients with diffuse large B-cell lymphoma (DLBCL). "
2.	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/01/2019 - "The CD37 targeting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin) is currently being evaluated in a clinical phase 2b trial for patients with follicular lymphoma (FL) and in a phase 1 trial for patients with diffuse large B-cell lymphoma (DLBCL). "
3.	Neoplasms (Cancer) 01/01/2014 - "177Lu-DOTA-HH1 was well tolerated at dosages about 10 times above those considered relevant for radioimmunotherapy in patients with B-cell derived malignancies.The"
4.	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/01/2015 - "177Lu-DOTA-HH1 (177Lu-HH1) is a novel anti-CD37 radioimmunoconjugate developed to treat non-Hodgkin lymphoma. "

Related Drugs and Biologics

1.	Immunoconjugates (Immunoconjugate)

Related Therapies and Procedures

1.	Radioimmunotherapy